Eylea and Ill-defined disorder - a phase IV clinical study of FDA data

Summary:

Ill-defined disorder is reported as a side effect among people who take Eylea (aflibercept), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Clopidogrel, and have Diabetic retinal oedema.

The phase IV clinical study analyzes which people have Ill-defined disorder when taking Eylea. It is created by eHealthMe based on reports of 27,819 people who have side effects when taking Eylea from the FDA, and is updated regularly.

What is Eylea?

Eylea has active ingredients of aflibercept. It is often used in macular degeneration. eHealthMe is studying from 27,868 Eylea users. Check the latest studies of Eylea.

What is Ill-defined disorder?

Ill-defined disorder is found to be associated with 1,465 drugs and 1,257 conditions by eHealthMe. Check the latest studies of Ill-defined disorder.

On Jul, 14, 2026

27,819 people reported to have side effects when taking Eylea.
Among them, 77 people (0.28%) have Ill-defined disorder.

Among these 77 people:

How long have people been on Eylea when they have Ill-defined disorder? *

What is the gender of people who have Ill-defined disorder when taking Eylea? *

female: 50 %
male: 50 %

What is the age of people who have Ill-defined disorder when taking Eylea? *

What are other drugs people take besides Eylea? *

What are other side effects people have besides Ill-defined disorder? *

Eye Pain: 7 people, 9.09%
Blindness Unilateral: 6 people, 7.79%
Death: 6 people, 7.79%
Intraocular Pressure Increased: 3 people, 3.90%
Visual Impairment: 3 people, 3.90%
Dizziness: 3 people, 3.90%
Acute Kidney Failure: 2 people, 2.60%
Ocular Discomfort (a generic expression when there is lack of ease in/about the eyes): 2 people, 2.60%
Loss Of Consciousness: 2 people, 2.60%
Drug Ineffective: 2 people, 2.60%

What are the existing conditions these people have? *

Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 15 people, 19.48%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 10 people, 12.99%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 7 people, 9.09%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 6 people, 7.79%
Age-Related Macular Degeneration: 5 people, 6.49%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 5 people, 6.49%
Asthma: 1 person, 1.30%
Blindness: 1 person, 1.30%
Conjunctival Haemorrhage (bleeding underneath the conjunctiva): 1 person, 1.30%
Corneal Neovascularisation (excessive ingrowths of blood vessels into the cornea): 1 person, 1.30%

* Approximation only. Some reports may have incomplete information.

Do you take Eylea and have Ill-defined disorder?

- Check whether Ill-defined disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eylea:

Eylea (27,868 reports)

Browse all side effects of Eylea:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ill-defined disorder:

Ill-defined disorder (1,465 drugs)

Browse all the conditions that are associated with Ill-defined disorder:

Ill-defined disorder (1,257 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on aflibercept (the active ingredients of Eylea) and Eylea (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.